VYCOR MEDICAL INC Reports Q2 2026 Financial Results

What Happened
VYCOR MEDICAL INC (VYCO) filed a Form 8-K on August 14, 2026 (Item 2.02) to announce a press release reporting its financial results for the three and six months ended June 30, 2026. The press release is furnished as Exhibit 99.1 to the 8-K. The company disclosed and reconciled certain non-GAAP measures used by management to evaluate operating performance.

Key Details

• Filing date: August 14, 2026; reporting period: three and six months ended June 30, 2026.
• Press release furnished as Exhibit 99.1 to the Form 8-K (Item 9.01).
• Non-GAAP measures disclosed: "non-GAAP Cash Operating Expenses" and "non-GAAP Cash Operating Loss," which exclude Depreciation and non-cash Stock Compensation.
• Company provided reconciliations of these non-GAAP measures to the comparable GAAP amounts and noted the usual limitations (not prepared in accordance with GAAP; may differ from peers).

Why It Matters
This 8-K gives investors the company’s latest quarterly results and management’s chosen operating metrics. The non-GAAP Cash Operating measures highlight cash-based operating performance by removing non-cash items (depreciation and stock-based compensation), which can make trends in cash burn or operating cost changes clearer. However, the company cautions these measures are supplemental to — not replacements for — GAAP results; investors should review the GAAP statements and the provided reconciliations when assessing Vycor’s financial condition.